Summit Therapeutics EBIT

The latest EBIT for SMMT is $-390M as of June 2026. That compares with $-680M in the prior-year period — up 43.0% year over year. That is below the sector sector average of $-27M. Investors often review this figure alongside Summit Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, SMMT's EBIT moved from $-680M to $-390M — a 43.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Summit Therapeutics's operating scale or balance-sheet position.

Against its sector companies, SMMT currently prints $-390M for EBIT, while the sector average sits near $-27M. That is roughly 1342.4% below the sector mean. Large gaps often invite a closer look at Summit Therapeutics's growth, margins, and balance sheet.

A EBIT figure of $-390M for SMMT is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-27M. Explore the charts below for those layers of context.

After noting SMMT's EBIT ($-390M), review year-over-year change from $-680M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.